Previous 10 | Next 10 |
2024-01-30 12:20:27 ET More on GSK GSK: Robust Earnings Report Expected, 2024 Outlook Is Key GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript) AbbVie Vs. GSK: Dual Dominance In Pharma GSK enters licensing deal with Elegen Watch GS...
2024-01-24 10:22:27 ET Summary Agenus Inc. has unveiled promising data from the NEST-1 study, showing the potential of the combination of botensilimab and balstilimab in colorectal cancer treatment. The combination demonstrated significant tumor regression and the elimination of c...
2024-01-22 10:09:06 ET More on Agenus Agenus: 2024 May Finally Be The Year For A Major Turnaround Agenus Inc. (AGEN) Q3 2023 Earnings Call Transcript GSK boosts sales forecast for Arexvy RSV vaccine Agenus Q3 2023 Earnings Preview Seeking Alpha’...
Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term disease-fr...
2024-01-18 09:24:32 ET Summary Agenus is a beaten-down immuno-oncology biotech stock that has not participated in the recent biotech rally despite a promising pipeline and multiple partnerships. The company's lead asset, botensilimab (+/- balstilimab), has shown promising results ...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Hea...
2023-12-24 09:45:00 ET Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. With the Fed possibly set to reverse course o...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combinati...
News, Short Squeeze, Breakout and More Instantly...
2024-05-07 17:45:24 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2024 Earnings Call May 07, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2024 Earnings Call Transcript
$100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch readiness activities Company has reestablished its market compliance with Nasdaq Listing Notable clinical...
Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activities Ligand entitled to royalties and milestone payments on six Agenus-partnered programs as well as royalties on future global net sales gener...